Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C8H15O2.Zn |
Molecular Weight | 351.816 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O
InChI
InChIKey=CHJMFFKHPHCQIJ-UHFFFAOYSA-L
InChI=1S/2C8H16O2.Zn/c2*1-2-3-4-5-6-7-8(9)10;/h2*2-7H2,1H3,(H,9,10);/q;;+2/p-2
Molecular Formula | Zn |
Molecular Weight | 65.409 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H15O2 |
Molecular Weight | 143.2035 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfCurator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Sources: http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf
Curator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
There is no available information related any biological or pharmacutical application of AMMONIUM PENTACHLOROZINCATE
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165https://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/10721938http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Curator's Comment: Glucarpidase hydrolyzes the methotrexate in the blood but cannot cross the blood-brain barrier, nor can it break down intracellular methotrexate.
Originator
Sources: http://sciencing.com/uses-zinc-carbonate-7889200.htmlhttps://www.webelements.com/zinc/history.htmlhttp://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194 |
|||
Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date-4.55328006E11 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date1.32675836E12 |
|||
Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date1.140048E12 |
|||
Primary | ZINC OXIDE Approved UseUnknown |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate. | 1991 Apr 1 |
|
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. | 1997 Feb |
|
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide. | 1997 May 16 |
|
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study. | 1999 May |
|
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age. | 2004 |
|
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium. | 2004 Jul 16 |
|
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function. | 2004 Jul 30 |
|
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2. | 2005 Apr 27 |
|
Elevated cortical zinc in Alzheimer disease. | 2006 Jul 11 |
|
Zinc homeostasis in aging: two elusive faces of the same "metal". | 2006 Summer |
|
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. | 2007 Nov |
|
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
|
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4. | 2013 Dec |
|
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles. | 2014 Jan |
|
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity. | 2014 May 16 |
|
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. | 2014 May 16 |
|
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents. | 2016 Oct 1 |
|
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. | 2016 Sep 21 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10978858
Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and
represented 40% of the recommended daily allowance of a male
adult human. This dose was administered in water solution at a
final volume of 1 mL per rat.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320875
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:33:13 UTC 2023
by
admin
on
Wed Jul 05 22:33:13 UTC 2023
|
Record UNII |
QL5435GI2S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C737
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
63869
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
C84246
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
QL5435GI2S
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
209-156-6
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
11180
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
DTXSID2042517
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
557-09-5
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | |||
|
M11599
Created by
admin on Wed Jul 05 22:33:13 UTC 2023 , Edited by admin on Wed Jul 05 22:33:13 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |